![Ann de Meulenaere](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ann de Meulenaere
Conseiller Juridique Général chez
Biocartis SA
Profil
Ann de Meulenaere currently works at Biocartis SA, as General Counsel from 2011.
Ms. de Meulenaere also formerly worked at KBC Private Equity NV, as Legal Advisor in 2010.
Ms. de Meulenaere received her graduate degree from Ghent University.
Postes actifs de Ann de Meulenaere
| Sociétés | Poste | Début |
|---|---|---|
Biocartis SA
 Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Conseiller Juridique Général | 01/06/2011 |
Anciens postes connus de Ann de Meulenaere
| Sociétés | Poste | Fin |
|---|---|---|
KBC Private Equity NV
 KBC Private Equity NV Investment ManagersFinance KBC Private Equity is an active, long-term manager which typically invests between €2 million and €50 million in medium-sized unlisted companies primarily in Belgium, Central and Eastern Europe. The firm targets performing businesses in diverse sectors which usually demonstrate a positive EBITDA of at least €1.5 million, focusing on companies which have built up a leading position in a specific sector and which have identified growth opportunities. Specific criteria apply for investments in the biotech industry. The firm takes both majority and minority interests in companies, partnering with the other shareholders and investee company management. In addition to providing equity and/or mezzanine financing, they aim to create value in areas where they are skilled, without participating in the day-to-day operational policy of the investee company. KBC Private Equity generally seeks a seat on the Board of Directors. The firm aims to contribute to investee companies by evaluating their internal and external growth opportunities, optimizing their financial structure, introducing new customer and supplier relationships, improving reporting systems and sharing specific industry knowledge. Their typical holding period is five to seven years for most of their investment projects. | Corporate Officer/Principal | 01/01/2010 |
Formation de Ann de Meulenaere
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
33
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Ghent University
 Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
KBC Private Equity NV
KBC Private Equity NV Investment ManagersFinance KBC Private Equity is an active, long-term manager which typically invests between €2 million and €50 million in medium-sized unlisted companies primarily in Belgium, Central and Eastern Europe. The firm targets performing businesses in diverse sectors which usually demonstrate a positive EBITDA of at least €1.5 million, focusing on companies which have built up a leading position in a specific sector and which have identified growth opportunities. Specific criteria apply for investments in the biotech industry. The firm takes both majority and minority interests in companies, partnering with the other shareholders and investee company management. In addition to providing equity and/or mezzanine financing, they aim to create value in areas where they are skilled, without participating in the day-to-day operational policy of the investee company. KBC Private Equity generally seeks a seat on the Board of Directors. The firm aims to contribute to investee companies by evaluating their internal and external growth opportunities, optimizing their financial structure, introducing new customer and supplier relationships, improving reporting systems and sharing specific industry knowledge. Their typical holding period is five to seven years for most of their investment projects. | Finance |
Biocartis SA
Biocartis SA Medical SpecialtiesHealth Technology Develops molecular diagnostic instruments for immunodiagnostics | Health Technology |
